Mesenchymal stromal cell therapy in Crohn's disease

0Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Mesenchymal stromal cells (MSCs) have been shown to possess the ability to home to injured tissues and actively participate in tissue repair. They have the ability to suppress immune responses both in vitro and in vivo and in animal models of experimental autoimmune diseases. In patients with acute and chronic immune diseases, this capacity of MSCs has also been observed. The tendency of MSCs to regenerate damaged tissue combined with their capability to regulate immune and inflammatory responses gives a strong rationale for using MSCs as a new treatment option in diseases characterized by inflammation with severe tissue damage, such as Crohn's disease. This chapter highlights the present knowledge on MSCs in Crohn's disease. The application of MSCs in experimental colitis models and clinical trials with MSCs in luminal and fistulizing Crohn's disease are discussed.

Cite

CITATION STYLE

APA

Molendijk, I., Hommes, D. W., & Duijvestein, M. (2013). Mesenchymal stromal cell therapy in Crohn’s disease. In Mesenchymal Stem Cell Therapy (pp. 207–215). Humana Press Inc. https://doi.org/10.1007/978-1-62703-200-1_11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free